

27th October, 2026

To,
The Manager - Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra East, Mumbai – 400 051,
Maharashtra, India

Dear Sir/Madam,

Sub: Outcome of Board Meeting - Disclosure of information under Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

**Ref: Neochem Bio Solutions Limited (SYMBOL: NEOCHEM, ISIN: INE21UM01018),
Half Year ended 30th September, 2026**

Pursuant to Regulations 30, 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board Meeting held today, i.e. Tuesday, 27th October, 2026, commenced at 05:20 P.M. and concluded at 06:30 P.M., has, inter alia, considered and approved the following:

1. Unaudited Standalone Financial Results of the Company for the Half Year ended on 30th September, 2026, along with the Limited Review Report thereon issued by M/s. Patel Mehta & Associates, Chartered Accountants, the Statutory Auditors of the Company.
2. **Appointment of Chief Financial Officer (Key Managerial Personnel):**
On the recommendation of the Nomination and Remuneration Committee, approved the appointment of CA Harshit Shah as the Chief Financial Officer and Key Managerial Personnel of the Company with effect from 27.10.2026.
3. **Appointment of Chief Commercial Officer (Senior Management Personnel):**
On the recommendation of the Nomination and Remuneration Committee, approved the appointment of Mr. Vikram Nair as the Chief Commercial Officer (CCO), designated as Senior Management Personnel of the Company, with effect from 27th October, 2026.

NEOCHEM BIO SOLUTIONS LIMITED

(Formerly Known as Neochem Technologies Private Limited)

303, W1, Opp. Vikramnagar Colony Off. Iskon-Ambli Road
Ahmedabad - 380 058 Gujarat, INDIA. | +91-79-3521 7792
admin@neochem.in | www.neochem.in

CIN No.: L24304GJ2017PLC097754 | GSTIN : 24AAFCN6825L1Z6



4. Change in designation of Mr. Pradip Ramniklal Solanki:

Consequent to the appointment of CA Harshit Shah as the Chief Financial Officer, Mr. Pradip Ramniklal Solanki has ceased to be the Chief Financial Officer and Key Managerial Personnel of the Company and has been re-designated under a Senior Management position of the Company with effect from 27th October, 2026. He continues in the employment of the Company.

The details required under Regulation 30 read with the SEBI circulars issued thereunder for items 2, 3 and 4 are enclosed as Annexure A.

This intimation will also be made available on the Company's website at www.neochem.in

We request you to kindly take the above information on record.

Thanking you.

For NEOCHEM BIO SOLUTIONS LIMITED

(Formerly known as Neochem Bio Solutions Private Limited and Neochem Technologies Private Limited)

Swapnil
Rameshbhai
Makati

Digitally signed by
Swapnil Rameshbhai
Makati
Date: 2026.10.27
18:49:01 +05'30'

SWAPNIL RAMESHBHAI MAKATI

Managing Director

DIN: 00188382

Encl.: As above

NEOCHEM BIO SOLUTIONS LIMITED

(Formerly Know as Neochem Technologies Private Limited)

303, W1, Opp. Vikramnagar Colony Off. Iskon-Ambli Road
Ahmedabad - 380 058 Gujarat, INDIA. | +91-79-3521 7792
admin@neochem.in | www.neochem.in

CIN No.: L24304GJ2017PLC097754 | GSTIN : 24AAFCN6825L1Z6



ANNEXURE A

Details of change in Key Managerial Personnel and Senior Management Personnel

Sr. No.	Particulars	CA Harshit Shah	Mr. Vikram Nair	Mr. Pradip Ramniklal Solanki
1	Reason for change, viz. appointment, resignation, removal, death or otherwise	Appointment as Chief Financial Officer and Key Managerial Personnel	Appointment as Chief Commercial Officer (CCO), Senior Management Personnel	Change in designation: ceased to be Chief Financial Officer and Key Managerial Personnel consequent to the appointment of the new CFO, and re-designated under the Senior Management Category of the Company.
2	Date of appointment / cessation and term of appointment	With effect from 27 th October, 2026.	With effect from 27 th October, 2026.	With effect from 27 th October, 2026.
3	Brief profile	Qualified Chartered Accountant with over 12 years of experience in finance, accounts, financial planning and analysis, taxation, statutory compliance, internal controls, treasury and working capital management. Previously General Manager – Finance & Accounts at IRM Offshore Marine & Engineers Pvt. Ltd. and Finance Head of the Retail Division at Iscon Balaji Foods Private Limited, with experience across aerospace, infrastructure, FMCG and other sectors. Experienced in financial reporting, budgeting, audit coordination, banking relationships and SAP implementation.	Senior specialty chemicals professional with more than 30 years of experience in sales, marketing, business development, product development and P&L management. Most recently Vertical Head – Textile Chemicals at Indofil Industries, leading strategy, key accounts, product portfolio and market expansion. Experienced across textiles, coatings, plastics, construction chemicals and petrochemicals. Holds a degree in Chemical Engineering and a diploma in business administration.	Associated with the Company since 2018. Holds a bachelor's degree in commerce from Gujarat University (1982) and has over 25 years of experience in accountancy and finance. He has overseen the financial management and strategic planning functions of the Company. Previously served as Accounts Head at Gaggar Enterprises Private Limited and as Executive Consultant at Safal Corporate Services Limited.
4	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable. He is not related to any Director or KMP of the Company.	Not applicable. He is not related to any Director or KMP of the Company.	Not applicable. He is not related to any Director or KMP of the Company.

NEOCHEM BIO SOLUTIONS LIMITED

(Formerly Known as Neochem Technologies Private Limited)

303, W1, Opp. Vikramnagar Colony Off. Iskon-Ambli Road
 Ahmedabad - 380 058 Gujarat, INDIA. | +91-79-3521 7792
 admin@neochem.in | www.neochem.in

CIN No.: L24304GJ2017PLC097754 | GSTIN : 24AAFCN6825L1Z6





INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT

To,
The Board of Directors

NEOCHEM BIO SOLUTIONS LIMITED

303, W1, Opp. PSP Projects House,
Inside lane of Timber Mart, Off. Iscon-Ambli Road,
Ambli, Ahmedabad – 380058

Limited Review Report on the unaudited standalone financial results of NEOCHEM BIO SOLUTIONS LIMITED for the half year ended 30 September 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We have reviewed the accompanying statement of unaudited standalone financial results of **NEOCHEM BIO SOLUTIONS LIMITED** ("the Company") for the half year ended 30 September 2026 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "SEBI LODR Regulations").

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. It has been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder, or other applicable accounting standards, as the case may be, and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the SEBI LODR Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity*, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists primarily of making inquiries of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Companies Act, 2013, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable accounting standards and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI LODR Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **PATEL MEHTA & ASSOCIATES**

Chartered Accountants

Firm Registration No.: 107773W

MALHAR MEHTA

Partner

Membership No.: 112226

UDIN No.: 26112226UHDGVA1264

Place: AHMEDABAD

Date: 27th October 2026

Sr. No.	Particulars	As at 30.09.2026 (Unaudited)	As at 31.03.2026 (Audited)
I	EQUITY SHARE CAPITAL		
1	Shareholders' Funds		
	Share Capital	1,712.08	1,712.08
	Reserves and Surplus	6,957.08	6,172.40
	Money Received against Share warrants	-	-
	Total Shareholders' Fund	8,669.16	7,884.47
2	Share Application money pending allotment		
3	Non Current Liabilities		
	Long Term Borrowings	541.58	69.80
	Deferred Tax Liabilities(net)	52.81	55.06
	Other Long term liabilities	-	-
	Long term Provisions	119.57	113.47
	Total Non-Current Liabilities	713.95	238.34
4	Current Liabilities		
	Short Term Borrowings	2,766.55	1,709.55
	Trade Payables	1,770.76	1,154.46
	Total Outstanding dues of MSME	1,162.79	773.06
	Total Outstanding dues Creditors other than MSME	607.97	381.40
	Other Current Liabilities	209.07	230.62
	Short Term Provisions	757.24	494.08
	Total Current Liabilities	5,503.62	3,588.71
	Total Equity and Liabilities	14,886.73	11,711.52
II	Assets		
1	Non Current Assets		
	Property, Plant and Equipment and Intangible Assets	-	-
	Property, Plant and Equipment	3,092.68	1,991.32
	Intangible assets	1.47	1.34
	Capital work in progress	275.58	5.84
	Non current investments	509.07	625.00
	Deferred Tax Liabilities(net)	-	-
	Long Term Loan loans and advances	-	-
	Other Non Current Assets	499.22	496.22
	Total Non current Assets	4,378.01	3,119.72
2	Current Assets		
	Inventories	4,040.97	2,925.39
	Trade receivables	4,813.49	4,872.34
	Cash and Cash Equivalent	18.49	18.10
	Short Term Loans and Advances	1,019.20	217.02
	Other Current Assets	616.57	558.95
	Total Current Assets	10,508.72	8,591.80
	Total	14,886.73	11,711.52



FOR AND ON BEHALF OF
NEOCHEM BIO SOLUTIONS LIMITED

Swapnil B. Makati

Swapnil B. Makati

Managing Director

DIN: 00188382

Place: Ahmedabad

Date: 27-10-2026

Neochem Bio Solutions Limited

CIN : L24304GJ2017PLC097754

303, W1, Opp. Vikramnagar Colony, Off. Iskcon-Ambli Road, Daskroi, Ahmedabad, Gujarat, 380058

Website: www.neochem.in | Email: admin@neochem.in | Tel: 079-35217792

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30 SEPTEMBER 2026

(₹ in Lakhs)

Sr. No.	Particulars	Half Year Ended 30.09.2026 (Unaudited)	Half Year Ended 31.03.2026 (Audited)	Half Year Ended 30.09.2025 (Audited)	Year Ended 31.03.2026 (Audited)
I	Revenue from operations	6,892.43	6,486.78	4,583.16	11,069.94
II	Other Income	37.12	134.88	135.03	269.91
III	Total Revenue (I + II)	6,929.55	6,621.66	4,718.19	11,339.85
IV	Expenses:				
	Cost of Material Consumed	4,851.54	4,342.08	3,015.20	7,357.29
	Changes in inventories	-75.23	190.80	-73.51	117.29
	Work in Progress and Stock in Trade	-	-	-	-
	Manufacturing Expenses	72.69	94.78	66.98	161.76
	Employee Benefit Expenses	421.05	409.87	406.72	816.59
	Finance Costs	126.79	152.29	198.23	350.52
	Depreciation and Amortization Cost	68.40	61.22	63.17	124.39
	Other Expenses	418.73	323.30	308.57	631.87
	Total Expenses (IV)	5,883.97	5,574.35	3,985.36	9,559.71
V	Profit/(Loss) before exceptional & extraordinary items	1,045.59	1,047.31	732.83	1,780.14
VI	Exceptional Items	-	61.89		61.89
VII	Profit/(Loss) before extraordinary items and Tax (V-VI)	1,045.59	985.43	732.83	1,718.25
VIII	Extraordinary Items				
IX	Profit/(Loss) Before tax (VII-VIII)	1,045.59	985.43	732.83	1,718.25
X	Tax expense:				
	Provision for Income Tax	263.15	302.42	186.66	489.08
	Short Provision for Previous year	-	31.61	-	31.61
	Current tax under MAT	-	-	-	-
	Deferred tax	-2.25	-2.89	-2.22	-5.10
	MAT Credit entitlement				
XI	Profit for the period from continuing operations	784.69	654.28	548.38	1,202.66
XII	Profit from discontinuing operation				-
XII	Tax Expense of discontinuing operations	-			-
XIV	Profit from discontinuing operations after tax	-	-	-	-
XV	Profit for the period [XI+XIV]	784.69	654.28	548.38	1,202.66
XVI	Earning per equity share:				
	(1) Basic	4.58	4.74	4.52	8.71
	(2) Diluted	4.58	4.74	4.52	8.71
	NOTES TO ACCOUNTS				

FOR AND ON BEHALF OF
NEOCHEM BIO SOLUTIONS LIMITED

Swapnil R. Makati
Managing Director

DIN: 00188382

Place : Ahmedabad

Date : 27-10-2026

Notes:

1. The Unaudited Financial Results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on October 27, 2026. The Statutory Auditors have carried out a Limited Review of the results for the half year ended 30 September 2026 and have issued an unmodified report.
2. These Unaudited financial statements have been prepared in accordance with the generally accepted accounting principles in India under the historical cost convention on accrual basis pursuant to section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other relevant provisions of the Companies Act, 2013.
3. One Query was received from investor during the period, same has been replied and therefore NIL complaint was pending as on September 30, 2026.
4. The figures for the half year ended 31 March 2026 are the balancing figures between the audited figures for the full financial year ended 31 March 2026 and the published audited figures for the half year ended 30 September 2025.
5. The Company deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Company considers it as one operating segment.
6. EPS for the half year are not annualised.
7. These Unaudited financial statements do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.
8. Previous year/ period figures have been regrouped to make them comparable with the current year/ period figures, which are not material.
9. During the period Company has recovered substantial amount from recent Cyber Fraud Incident held in July'26 and the balance is in the process of recovery with the assistance of the legal authorities.

FOR AND ON BEHALF OF,
Neochem Bio Solutions Limited



Swapnil R Makati
Managing Director

DIN: 00188382

Ahmedabad, October 27, 2026



Neochem Bio Solutions Limited

CIN : L24304GJ2017PLC097754

303, W1, Opp. Vikramnagar Colony, Off. Iskcon-Ambli Road, Daskroi, Ahmedabad, Gujarat, 380058

Website: www.neochem.in | Email: admin@neochem.in | Tel: 079-35217792

Unaudited CASH FLOW STATEMENT FOR THE PERIOD ENDED 30th Sept, 2026

(₹ in Lakhs)

Particulars	Half Year Ended 30.09.2026 (Unaudited)	Year Ended 31.03.2026 (Audited)
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit Before Taxation	1,045.59	1,718.25
Add :		
Depreciation	68.40	124.39
Interest expense	126.79	350.52
Bad Debt	0.00	0.00
Loss on sale of Property, Plant and Equipment	0.00	4.50
Less :	0.00	0.00
Subsidy Income	0.00	0.00
Interest income	27.34	13.04
Profit on sale of Investment	0.00	0.13
Operating profit before working capital changes :	1,213.43	2,184.50
Add/Less: Changes in working capital		
Increase/(Decrease) in Trade Payables	616.30	-516.80
(Increase)/Decrease in Inventories	-1,115.58	-549.84
(Increase)/Decrease in Trade Receivables	58.85	-2,344.66
Increase/(Decrease) in Other Current Liabilities	-21.54	-79.95
(Increase)/Decrease in Long Term Loans & advances	0.00	0.00
(Increase)/Decrease in Short Term Loans & advances	-802.18	-94.48
Increase/(Decrease) in Other Provisions	6.09	73.64
(Increase)/Decrease in Non Current Assets	-3.00	212.47
(Increase)/Decrease in Other Current Assets	-57.63	-282.44
Less : Adjustment for Taxes :	0.00	0.00
Direct taxes paid	0.00	296.22
Tax adjustment of earlier year		
Cash Generated/ (used in) from operating activities (A)	-105.25	-1,693.78
B. CASH FLOW FROM INVESTMENT ACTIVITIES	0.00	0.00
Interest income	27.34	13.04
Proceeds from sale of investments	115.93	-625.00
	0.00	0.00
Purchase of investments	0.00	0.00
Proceeds from sale of Fixed Assets	5.84	40.86
Purchase of fixed assets	-1,445.46	-295.44
Investment in Intangible Assets	0.00	0.00
Net cash generated/ (used in) from investing Activities (B)	-1,296.35	-866.55
C. CASH FLOW FROM FINANCING ACTIVITIES :		
Proceeds from long term borrowings	471.78	-1,358.11
Repayment of long term borrowing	0.00	0.00
Proceeds from short term borrowings	1,057.00	-424.97
Repayment of short term borrowings	0.00	0.00
Proceeds from issue of equity shares	0.00	4,706.54
Interest paid	-126.79	-350.52
Net Cash generated/ (used in) from financing activities (C)	1,401.99	2,572.94
Net increase or decrease in Cash and Cash Equivalents (A+B+C)	0.39	12.61
Opening cash and cash equivalents	18.10	5.50
Closing cash and cash equivalents	18.49	18.10

Notes

1. Statement of cash Flow has been prepared under the indirect method as set out in AS 3 on "Statement of Cash Flows". Specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014.

2. Reconciliation of cash and cash Equivalents as per the Statement of Cash Flow.

Particulars	As At Sept 30, 2026	As At March 31, 2026
Balances with Banks		
In Current accounts	0.46	0.20
Cash on hand	18.03	17.91
Fixed deposits having maturity less than 12 months	0.00	0.00
Cash and cash equivalents as at the end of the year (Refer Note 20)	18.49	18.10
3. Figures in bracket indicate cash outflow	0.00	0.00

FOR AND ON BEHALF OF
NEOCHEM BIO SOLUTIONS LIMITED

Swapnil R Makati
Managing Director
DIN: 00188382

Place : Ahmedabad
Date: 27-10-2026